CN106668285A - Pharmaceutical composition for preventing and curing lumbar disc herniation - Google Patents
Pharmaceutical composition for preventing and curing lumbar disc herniation Download PDFInfo
- Publication number
- CN106668285A CN106668285A CN201611132975.5A CN201611132975A CN106668285A CN 106668285 A CN106668285 A CN 106668285A CN 201611132975 A CN201611132975 A CN 201611132975A CN 106668285 A CN106668285 A CN 106668285A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- weight
- ethanol
- weight portion
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 57
- 206010050296 Intervertebral disc protrusion Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 57
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 241001453749 Doryopteris concolor Species 0.000 claims abstract description 24
- 241000201354 Sopubia Species 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 126
- 238000010521 absorption reaction Methods 0.000 claims description 28
- 238000000605 extraction Methods 0.000 claims description 28
- 239000011148 porous material Substances 0.000 claims description 28
- 239000011347 resin Substances 0.000 claims description 28
- 229920005989 resin Polymers 0.000 claims description 28
- 239000012467 final product Substances 0.000 claims description 24
- 229930190125 Sanguisorbin Natural products 0.000 claims description 23
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 claims description 23
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 238000007796 conventional method Methods 0.000 claims description 4
- 241000997485 Hemionitis arifolia Species 0.000 claims description 2
- MFIXLWYJTVEVGO-YHGWSDCJSA-N O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CC[C@H]([C@@]([C@H]14)(C)O)C)C(O)=O)[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CC[C@H]([C@@]([C@H]14)(C)O)C)C(O)=O)[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O MFIXLWYJTVEVGO-YHGWSDCJSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- MFIXLWYJTVEVGO-DNOHTNDQSA-N ilexoside B Natural products C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O MFIXLWYJTVEVGO-DNOHTNDQSA-N 0.000 abstract description 3
- WFDGBBHAJUVQKE-UHFFFAOYSA-N ziyu-glycoside II Natural products CC1(O)CCCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OCC(O)C(O)C6O)C(C)(C)C5CCC34C)C12)C(=O)O WFDGBBHAJUVQKE-UHFFFAOYSA-N 0.000 abstract description 3
- 241001219659 Climacium dendroides Species 0.000 abstract description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 abstract 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 abstract 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- 241001164374 Calyx Species 0.000 description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- IXHACUTUTOCSJE-UHFFFAOYSA-N Cyclolaudenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCC(C)C(C)=C)C)CCC3(C)C1CC2 IXHACUTUTOCSJE-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- IXHACUTUTOCSJE-HWTFXIFRSA-N cyclolaudenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CC[C@H](C)C(C)=C)C)CC[C@@]3(C)[C@@H]1CC2 IXHACUTUTOCSJE-HWTFXIFRSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 240000001972 Gardenia jasminoides Species 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- DLTTWXWDLCGBRD-UHFFFAOYSA-N Hydroxyhopane Natural products CC12CCCC(C)(C)C1CCC1(C)C2CCC2C3(C)CCC(C(C)C)C3(O)CCC21C DLTTWXWDLCGBRD-UHFFFAOYSA-N 0.000 description 2
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241001074085 Scophthalmus aquosus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 229940047495 celebrex Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- KIYYUMANFSBVAV-MZIWDXLGSA-N (3r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13bs)-5a,5b,8,8,11a,13b-hexamethyl-3-propan-2-yl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysen-9-ol Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)C[C@H](O)C(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(C)C KIYYUMANFSBVAV-MZIWDXLGSA-N 0.000 description 1
- HHXYJYBYNZMZKX-PYQRSULMSA-N 22(29)-Hopene Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(=C)C HHXYJYBYNZMZKX-PYQRSULMSA-N 0.000 description 1
- PNJBOAVCVAVRGR-UDCAXGDQSA-N 22-Hopanol Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(C)(O)C PNJBOAVCVAVRGR-UDCAXGDQSA-N 0.000 description 1
- HHXYJYBYNZMZKX-UHFFFAOYSA-N 3,4:15,16-diepoxy-7-oxo-13(16),14-clerodadien-20,12-olide-(3alpha,4alpha)-form Natural products C12CCC3C4(C)CCCC(C)(C)C4CCC3(C)C1(C)CCC1C2(C)CCC1C(=C)C HHXYJYBYNZMZKX-UHFFFAOYSA-N 0.000 description 1
- QCGMIFBWAQSUQY-UHFFFAOYSA-N 31-Norcyclolaudenol Natural products C1CC2(C)C(C(CCC(C)C(C)=C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 QCGMIFBWAQSUQY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 1
- 241000555268 Dendroides Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- ZHDRLFGZQZCZKX-BQOUFORSSA-N Fernene Chemical compound CC1(C)CCC[C@]2(C)C3=CC[C@@]4(C)[C@@H]5CC[C@H](C(C)C)[C@@]5(C)CC[C@]4(C)[C@H]3CC[C@H]21 ZHDRLFGZQZCZKX-BQOUFORSSA-N 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 241001166194 Geranium wilfordii Species 0.000 description 1
- 206010019477 Hemivertebra Diseases 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 241000358485 Leskea Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000737257 Pteris <genus> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000921453 Rhodobryum Species 0.000 description 1
- 206010064932 Sacralisation Diseases 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- ZHDRLFGZQZCZKX-UHFFFAOYSA-N UNPD33269 Natural products CC1(C)CCCC2(C)C3=CCC4(C)C5CCC(C(C)C)C5(C)CCC4(C)C3CCC21 ZHDRLFGZQZCZKX-UHFFFAOYSA-N 0.000 description 1
- KYBLAIAGFNCVHL-VKWWBDAGSA-N Zeorin Natural products OC(C)(C)[C@@H]1[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@@H]([C@@H](O)C4)C(C)(C)CCC5)CC3)CC2)CC1 KYBLAIAGFNCVHL-VKWWBDAGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- KYBLAIAGFNCVHL-UHFFFAOYSA-N alpha-zeroin Natural products C12CCC3C4(C)CCCC(C)(C)C4C(O)CC3(C)C1(C)CCC1C2(C)CCC1C(C)(O)C KYBLAIAGFNCVHL-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003164 cauda equina Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000010159 dioecy Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 description 1
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- CBZFLMNNXKRPHN-UHFFFAOYSA-N hopene-a Natural products C12CCC3C4(C)CCCC(C)(C)C4CCC3(C)C1(C)CCC1C2(C)CCC1=C(C)C CBZFLMNNXKRPHN-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- KYBLAIAGFNCVHL-PMVHANJISA-N zeorin Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1[C@@H](O)C[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1C(C)(O)C KYBLAIAGFNCVHL-PMVHANJISA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and curing lumbar disc herniation and a preparation method thereof. The pharmaceutical composition is prepared by proportioning the following raw material medicines: sopubia stricta, climacium dendroides, geniposide, ziyuglycoside II and doryopteris concolor. The pharmaceutical composition can be made into various dosage forms according to a conventional preparation process, and has a remarkable treatment effect in preventing and curing lumbar disc herniation.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition and its system for preventing and treating protrusion of lumber intervertebral disc
Preparation Method.
Background technology
The protrasion of the lumbar intervertebral disci is the common disease in people's daily life, the main cause for causing be lumbar disc damage,
Regression, Nucleus pulposus stimulate, compressing root is neural or cauda equina nerve, and the sings and symptoms of protrusion of lumber intervertebral disc is main with lumbocrural pain
Based on, it is orthopaedics frequently-occurring disease, common disease.Clinical statisticses show that it is Orthopaedics Clinic the most common that lumber ertebral disc prominent (de-) goes out disease
The reason for one of illness is also pain in waist and lower extremities the most common.History is reviewed, interverbebral disc is just described early in Vesalius in 1543
Outward appearance.The twenties in 20th century, the Shmorl of Germany has successively delivered the article of 11 relevant interverbebral discs dissections and pathology, to intervertebral
Disk has done wide research.1932, Barr propose first protrusion of lumber intervertebral disc be pain in waist and lower extremities may the reason for.Thereafter,
Barr and Mixter propose the concept and treatment method about the protrasion of the lumbar intervertebral disci first.Hereafter, to lumber ertebral disc
The basic research that prominent (de-) goes out disease is also progressively goed deep into, so as to more improve the effect of this sick clinical diagnosis and treatment.Many institute's weeks
Know, lumber ertebral disc bears powerful compression in the load of backbone and motion.About after 20 years old, interverbebral disc starts to move back
Become, and constitute the Basic disease cause of the protrasion of the lumbar intervertebral disci.Additionally, the protrasion of the lumbar intervertebral disci is relevant with following factors：(1) wound：
Observation to clinical case shows：Wound is the key factor of disc herniation, particularly children and teen-age morbidity, therewith
It is closely related.In the slight load of backbone and quick rotation, the level of fibrous ring can be caused to rupture, and compression mainly makes cartilage
Cartilaginous end-plate rupture.Also it is believed that, wound is the inducement for causing disc herniation, and original lesion is in painless nucleus pulposus is charged into
Layer fibrous ring, and wound makes nucleus pulposus further be projected into outside to have the outer layer fiber ring of innervation, so as to cause pain.(2)
Occupation：Occupation is very close with the relation that lumber ertebral disc prominent (de-) goes out, for example, automobile and operator on the tractor are chronically at seat
And jounce condition, so that in driving, intradiscal pressure is higher, up to 0.5kPa/cm2, the pressure in stepping on clutch
1kPa/cm2 can be increased to, protrusion of lumber intervertebral disc is easily caused.Heavy physical labour and weightlifting person are engaged in because of over load more
Intervertebral disc degeneration is easily caused, because under stooped over position, if carrying the weight of 20kg, the pressure in interverbebral disc rises to 30kPa/
More than cm2.(3) inherent cause：The protrasion of the lumbar intervertebral disci has the report that familial is fallen ill, and material is less at home；Additionally, statistics
Numeral shows that the incidence of disease of American Indian, African black race and Yin Niute people is evident as low, its original compared with other national incidences of disease
Because needing further research.(4) waist sacrum congenital anomaly：Lumbosacral segment deformity can increase the incidence of disease, including sacralization, sacral waist
Change, hemivertebra, Minor articulus deformity and articular process are asymmetric etc..Above-mentioned factor can change the stress that lower lumbar spine bears
Become, so that constituting intradiscal pressure raises and easily occur one of regression, the factor damaged.Cause the induction of the protrasion of the lumbar intervertebral disci
Factor is complex, though various experiments have been carried out at present, due to inferential, the distortion of fresh cadaver sample of zoopery
Property, and go the limitation of backbone surrounding tissue Biomechanics test etc., not yet really find out at present induce this disease it is definite because
Element and its mechanism, will need from now on further investigation.
Trifid sopubia herb：This product is complete for the short hat grass Sopubia trfida Buch.-Ham.'s of Scrophulariaceae Sopubia plant
Grass.Summer, autumn harvesting, dry.【Nature and flavor】Bitter；It is puckery；It is warm in nature.【Indication】Dispelling wind and eliminating dampness；Wet inner analgesic.Main chill is wet
Numbness；Stomachache with cool feeling；Lumbago due to the kidney deficiency.【Former phytomorph】The short careless annual herb of hat, 40-90cm high.Root is carefully cylindrical.Stem list
One or more numbers, uprightly, top multi-branched, branch tool corner angle and striped, by pubescence.Leaf opposite or alternate；The full shape synthesis circle of blade
Taper；Luxuriant leave shape；Bennet is about 1cm, there is a pair of brill shape squamellas at nearly top；Calyx taper；Bract is lobate；Bennet is about 1cm,
There are a pair of brill shape squamellas at nearly top；Calyx bracelet shape, pipe portion 10, rib of tool, calyx tooth 5 is wider than in length, triangle, internal and edge without
There is wool；Corolla yellow or purple, are about 1cm, manage extremely short, sliver 5, carry out, obovate greatly, and circle is blunt, near equal；Stamen 4,
The last two, filigree is born in the top of tube, and the Room of flower pesticide 1 is degenerated and narrow；Style is single, harbors.Capsule is spherical, and tip is flat
And be recessed, it is shorter or isometric than calyx.Shape of the seed is uneven, the reticulate pattern for having elongated hole.The month at florescence 6-7, fruiting period September.Record big in Chinese medicine
Dictionary.
10000 years moss：This product is ten thousand Nian Xian sections, 10000 years Rhodobryum plants, 10000 years moss Climacium dendroides（Hedw.）
The plant of Web.et Mohr ［ Leskea dendroides Hedw. ］.Spring, summer harvesting, clean, and dry.【Nature and flavor】It is bitter；
It is cold.【Indication】Removing damp-heat；Stimulate the circulation of the blood and cause the muscles and joints to relax.Main rheumatism internal lesion caused by overexertion；Arthralgia and myalgia.【Chemical analysis】Containing cupreol (β-
Sitosterol), stigmasterol (stigmasterol), ergosterol (ergosterol), campesterol (campesterol),
Cyclolaudenol (cyclolaudenol), 31- removes first cyclolaudenol (31-norcyclolaudenol), and metal
Elemental iron, manganese, zinc, copper etc..【Former phytomorph】Plant is thick in tree-like, and subterranean stem crawls to grow wild, and has rhizoid and film quality squama
Shape leaflet.The aerial stem of plant is upright, multi-branched, up to 15-20cm, the densely covered green palea of branch.The leaf on stem top and branched base part
Blade is in ovate triangle wide or ovum shape lanceolar, and base portion is slightly downward.Middle rib is single, and up in termination before blade tip, blade top is thin
The narrow rhombus of born of the same parents, leaf corner cell is circular, semi-transparent clear.The blade on branch top is smaller, long and narrow lanceolar, leaf edge sawtooth reach in
Middle part.Dioecism.Seta is elongated, 2-4cm long, red；Sporangium is upright, and cylindricality long has more；The female shape of opercule circle high；Capsule balaclava
Shape, the full sporangium of clad.Record in dictionary of medicinal plant.
Doryopteris concolor (Langsd et Fisch.) Kuhn：This product is Sinopteridaceae Doryopteris concolor (Langsd et Fisch.) Kuhn platymiscium Doryopteris concolor (Langsd et Fisch.) Kuhn Doryopteris concolor（Langsd.
Et Fisch.）The herb of Kuhn [Pteris concolor Langsd. Et Fisch.].Summer, autumn harvesting, clean, and shine
It is dry.【Nature and flavor】Slight bitter；It is puckery；It is cool.【Return through】Enter bladder, the warp of liver two.【Indication】Reducing fever and causing diuresis；Hemostasis.Main stranguria；Wound goes out
Blood.【Chemical analysis】Leaf contains 22（29）- hopenen [hop-22（29）- ene], hopanol（hydroxyhopane）, 6,22- what
Handkerchief glycol（zeorin）, freidelin（friedelin）, fern -9（11）- alkene [fern-9（11）- ene], squalene
（squalene）.【Former phytomorph】Terrestrial pteridophyte, plant 20-35cm high.Rhizome is short and tiny, near upright, is draped over one's shoulders pin
There is 1 chestnut black middle rib of thickness in shape scale, light brown, center.Leaf papery, fasciation, a type；Petiole, rachis and pinna rachis are bright
Atropurpureus, petiole 6-24cm long is dredged by brown undercoat, and rear dipped beam is slided, and base portion is by scale；The nearly pentagon of blade, length and width are closely equal,
4-8cm, acumen, the wealthy heart-shaped or halberd shape of base portion, several to be split for third, central 1 wealthy rhombus, pinniform drastic crack, 3.5-5cm long is wide
2-4cm, base portion wealthy wedge shape is downward in rachis, and base portion 1 is maximum to pinnule, pinniform partly split or it is shallow split, side life accessory pinna triangle,
3-4.5cm long, 2.5-3.5cm wide, the downward wealthy wing downward with central 1 of base portion are connected, lower base pinnule speciality, pinniform
Drastic crack, the 2nd pinnule has bastard, and remaining full edge, upside pinnule is short, full edge；Vein pinniform, scun dichotomy.Spore
Sorus is distributed along sliver both sides of the edge, tip and incises infertility；Indusium full edge.Record in dictionary of medicinal plant.
Gardenoside（Gardenoside）：CAS 24512-62-7, molecular formula C17H24O11, molecular weight 404.37.【It is biological
Activity】Discharge function, choleretic effect.【Ingredient origin】Cape jasmine Gardenia jasminoides [Syn.Gardenia
florida)。
Sanguisorbin II（Ziyuglycoside II）：CAS 35286-59-0, molecular formula C35H56O8, molecular weight
604.81.【Bioactivity】Cool blood, hemostasis.【Ingredient origin】Garden burnet Sanguisorba officinalis.
2 bulk drug chemical constitutions：
Sanguisorbin II（Ziyuglycoside II）Gardenoside（Gardenoside）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of medicine group of effective preventing and treating protrusion of lumber intervertebral disc
Compound and preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for being made the bulk drug of the pharmaceutical composition of the preventing and treating protrusion of lumber intervertebral disc be：
10000 years moss 420-430 weight portion Gardenoside 230-260 weight portion sanguisorbins of trifid sopubia herb 5200-5300 weight portions
II50-60 weight portion Doryopteris concolor (Langsd et Fisch.) Kuhn 700-900 weight portions.
The pharmaceutical composition of preventing and treating protrusion of lumber intervertebral disc is preferably used in, is made up of the bulk drug of following weight portion：
5250 weight portion of trifid sopubia herb, 10000 years weight portion sanguisorbin II55 weight portions of 425 weight portion Gardenoside of moss 245 are black
The weight portion of heart fern 800.
A kind of pharmaceutical composition for preventing and treating protrusion of lumber intervertebral disc, it is characterised in that pharmaceutical composition can be using galenic pharmacy
Conventional method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for preventing and treating protrusion of lumber intervertebral disc, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine group
Into preventing and treating protrusion of lumber intervertebral disc medicine.
A kind of preparation method of the pharmaceutical composition for preventing and treating protrusion of lumber intervertebral disc, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：10000 years moss 420-430 weight portion Gardenosides of trifid sopubia herb 5200-5300 weight portions
230-260 weight portion sanguisorbin II50-60 weight portion Doryopteris concolor (Langsd et Fisch.) Kuhn 700-900 weight portions；
Preparation method：
（1）Trifid sopubia herb, 10000 years moss, Gardenoside, sanguisorbin II, Doryopteris concolor (Langsd et Fisch.) Kuhns are taken by bulk drug proportioning, is mixed, use weight percent
Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 23%, and extraction time is 21 times, and each extraction time is 67 hours, molten every time
Agent consumption is 55 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close
Degree 1.03, filtration, liquid is first washed with water by SIP1300 large pore resin absorption columns, then with the second of weight percent concentration 12%
Alcoholic solution elutes SIP1300 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 12%, reclaims ethanol, concentration
Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 42% as solvent, heating and refluxing extraction 34 times is carried every time
The time is taken for 0.1 hour, each solvent load is 34 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned
Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water, then use weight by D151 large pore resin absorption columns
The ethanol solution of percent concentration 53% elutes D151 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 53%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
The preparation method of preferred a kind of pharmaceutical composition for preventing and treating protrusion of lumber intervertebral disc, it is characterised in that as follows
Prepare：
The composition and weight portion of bulk drug be：5250 weight portion of trifid sopubia herb, 10000 years weight portions of 425 weight portion Gardenoside of moss 245
The weight portion of sanguisorbin II55 weight portions Doryopteris concolor (Langsd et Fisch.) Kuhn 800；
Preparation method：
（1）Trifid sopubia herb, 10000 years moss, Gardenoside, sanguisorbin II, Doryopteris concolor (Langsd et Fisch.) Kuhns are taken by bulk drug proportioning, is mixed, use weight percent
Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 23%, and extraction time is 21 times, and each extraction time is 67 hours, molten every time
Agent consumption is 55 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close
Degree 1.03, filtration, liquid is first washed with water by SIP1300 large pore resin absorption columns, then with the second of weight percent concentration 12%
Alcoholic solution elutes SIP1300 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 12%, reclaims ethanol, concentration
Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 42% as solvent, heating and refluxing extraction 34 times is carried every time
The time is taken for 0.1 hour, each solvent load is 34 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned
Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water, then use weight by D151 large pore resin absorption columns
The ethanol solution of percent concentration 53% elutes D151 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 53%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for preventing and treating protrusion of lumber intervertebral disc, it is characterised in that pharmaceutical composition can be adopted
Piece agent or capsule or dripping pill are prepared with the conventional method of galenic pharmacy.
A kind of preparation method of the pharmaceutical composition for preventing and treating protrusion of lumber intervertebral disc, it is characterised in that pharmaceutical composition and chemistry
Medicine or Chinese medicine composition preventing and treating protrusion of lumber intervertebral disc medicine.
Pharmaceutical composition preventing and treating protrusion of lumber intervertebral disc is evident in efficacy.
Specific embodiment
Embodiment 1：Prevent and treat pharmaceutical composition of protrusion of lumber intervertebral disc and preparation method thereof
Prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition bulk drug composition and weight portion be：10000 years moss of trifid sopubia herb 5250g
425g Gardenoside 245g sanguisorbin II55g Doryopteris concolor (Langsd et Fisch.) Kuhns 800g；
Preparation method：
（1）Trifid sopubia herb, 10000 years moss, Gardenoside, sanguisorbin II, Doryopteris concolor (Langsd et Fisch.) Kuhns are taken by bulk drug proportioning, is mixed, use weight percent
Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 23%, and extraction time is 21 times, and each extraction time is 67 hours, molten every time
Agent consumption is 55 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close
Degree 1.03, filtration, liquid is first washed with water by SIP1300 large pore resin absorption columns, then with the second of weight percent concentration 12%
Alcoholic solution elutes SIP1300 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 12%, reclaims ethanol, concentration
Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 42% as solvent, heating and refluxing extraction 34 times is carried every time
The time is taken for 0.1 hour, each solvent load is 34 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned
Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water, then use weight by D151 large pore resin absorption columns
The ethanol solution of percent concentration 53% elutes D151 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 53%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Prevent and treat pharmaceutical composition of protrusion of lumber intervertebral disc and preparation method thereof
Prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition bulk drug composition and weight portion be：10000 years moss of trifid sopubia herb 5200g
430g Gardenoside 230g sanguisorbin II60g Doryopteris concolor (Langsd et Fisch.) Kuhns 700g；
Preparation method：
（1）Trifid sopubia herb, 10000 years moss, Gardenoside, sanguisorbin II, Doryopteris concolor (Langsd et Fisch.) Kuhns are taken by bulk drug proportioning, is mixed, use weight percent
Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 23%, and extraction time is 21 times, and each extraction time is 67 hours, molten every time
Agent consumption is 55 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close
Degree 1.03, filtration, liquid is first washed with water by SIP1300 large pore resin absorption columns, then with the second of weight percent concentration 12%
Alcoholic solution elutes SIP1300 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 12%, reclaims ethanol, concentration
Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 42% as solvent, heating and refluxing extraction 34 times is carried every time
The time is taken for 0.1 hour, each solvent load is 34 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned
Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water, then use weight by D151 large pore resin absorption columns
The ethanol solution of percent concentration 53% elutes D151 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 53%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Prevent and treat pharmaceutical composition of protrusion of lumber intervertebral disc and preparation method thereof
Prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition bulk drug composition and weight portion be：10000 years moss of trifid sopubia herb 5300g
420g Gardenoside 260g sanguisorbin II50g Doryopteris concolor (Langsd et Fisch.) Kuhns 900g；
Preparation method：
（1）Trifid sopubia herb, 10000 years moss, Gardenoside, sanguisorbin II, Doryopteris concolor (Langsd et Fisch.) Kuhns are taken by bulk drug proportioning, is mixed, use weight percent
Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 23%, and extraction time is 21 times, and each extraction time is 67 hours, molten every time
Agent consumption is 55 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close
Degree 1.03, filtration, liquid is first washed with water by SIP1300 large pore resin absorption columns, then with the second of weight percent concentration 12%
Alcoholic solution elutes SIP1300 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 12%, reclaims ethanol, concentration
Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 42% as solvent, heating and refluxing extraction 34 times is carried every time
The time is taken for 0.1 hour, each solvent load is 34 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned
Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water, then use weight by D151 large pore resin absorption columns
The ethanol solution of percent concentration 53% elutes D151 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 53%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 500g of Example 1, adds starch 400g, mixes, and granulation is dried, plus microcrystalline cellulose 122g, stearic
Sour magnesium 4g, mixes, and is pressed into 5000, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 323g of Example 2, adds starch 278g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid
Magnesium, mixes, and encapsulated 2100, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 350g water-baths and boil molten, add the pharmaceutical composition 12.3g of embodiment 3, fully
Stir, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 4 DEG C, and drip internal-and external diameter is 7.0/
2.0 (mm/mm), drip is 2.7cm away from liquid level, and drop speed is optimum condition with every point 49 drop, and the cold of dripping pill surface is blotted with cotton
Solidifying agent, obtains final product medicament composition dropping pills.
Embodiment 7：Prevent and treat the pharmaceutical composition of protrusion of lumber intervertebral disc
Prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition bulk drug composition and weight portion be：
10000 years weight portions of 480 weight portion sanguisorbin II65 weight portions Doryopteris concolor (Langsd et Fisch.) Kuhn of moss 860.
Embodiment 8：Prevent and treat the pharmaceutical composition of protrusion of lumber intervertebral disc
Prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 240 weight portion sanguisorbin II70 weight portions Doryopteris concolor (Langsd et Fisch.) Kuhn of Gardenoside 950.
Embodiment 9：Prevent and treat the pharmaceutical composition of protrusion of lumber intervertebral disc
Prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 270 weight portion sanguisorbin II50 weight portions Doryopteris concolor (Langsd et Fisch.) Kuhn of Gardenoside 750.
Experimental example 1：Prevent and treat the experimental study of protrusion of lumber intervertebral disc
1 data and method
1.1 physical data
Choose the patient 46 for receiving treatment protrusion of lumber intervertebral disc for 2 months -2014 years 2 months 2013 in our hospital, wherein male patient
23, account for the 50% of total number of persons, female patient 23 accounts for the 50% of total number of persons, 17~63 years old age, averagely（41.54±6.02）
Year.46 patients are randomly divided into observation group and control group according to random controls method, and two groups respectively have patient 23.All trouble
Person inflicts heavy losses on or received lumbar surgery treatment without lumbar vertebrae.
1.2 treatment method
1.2.1 observation group
Observation group uses pharmaceutical composition（The pharmaceutical composition of embodiment 1）Treated, all patients are with pharmaceutical composition
Square foundation, can add and subtract medicine and it is treated according to patient's different situations.If patient's waist or lower limb pain, in base
Activating blood and removing stasis drug, such as frankincense, rhizoma cyperi are added in plinth side；If patient's waist-leg portion is caught cold and overcast and rainy its pain is aggravated, perverse trend
On surface, wind-damp dispelling is added to remove obstruction in channels to relieve pain medicine, such as caulis sinomenii, caulis trachelospermi, geranium wilfordii on square foundation；If patient's lower limb
Swelling pain, and pain is difficult to cure more for a long time, and clearing damp and promoting diuresis medicine, such as cassia twig, Poria cocos are added on square foundation；If
Patient's numb limb, adds arthralgia eliminating medicine with function of dredging meridian passage, such as earthworm, centipede on square foundation；If patient occurs in end-stage disease
The symptom of soreness and weakness of waist and knees, adds kidney tonifying, essence replenishing medicine, such as thizoma curculiginis, matrimony vine on square foundation.Be decocted in water for oral dose 400 mL, daily 2 times,
Daily 1 dose, medicine residue is contained into cloth bag after medicine decocting, hot compress treats January in waist.
1.2.2 control group
Control group patient closes Mecobalamin and is treated using oral Celebrex.Daily 200 mg of Celebrex, takes at twice；First cobalt
The daily 500 μ g of amine piece, divide 3 times and take.
1.3 criterion
According to《In cure the desease Standardization of diagnosis and curative effect》Lumbar Intervertebral Disc standard.Recovery from illness：The symptoms such as patient's lumbocrural pain disappear
Lose, activity and life are normal, carry out follow-up without recurrence within 3 months after treatment；It is effective：The symptoms such as patient's lumbocrural pain disappear substantially,
Do not influence routine work, but it is overworked or mild pain, or conditions of patients can be produced to be turned by severe during because of weather reason
For slight；Effectively：The symptoms such as patient's lumbocrural pain have slight improvement, but unstable condition, can not do heavy physical labour；It is invalid：
The symptoms such as patient's lumbocrural pain are unchanged, or even aggravate.
1.4 statistical method
Two groups of data carry out statistical procedures using SPSS16.0 softwares, are checked using card side and t, if（P ＜ 0.05）
Then represent that difference is statistically significant.
2 results
2.1 clinical treatment
Observation group patient, 10 patient's recoveries from illness, 6 patients are effective, and effectively, 2 patients are invalid, and total effective rate is for 5 patients
91.30%；4 patient's recoveries from illness of control group patient, 5 patients are effective, and effectively, 8 patients are invalid, and total effective rate is for 6 patients
65.22%, two groups of comparing differences are statistically significant（P<0.05）.Refer to table 1.
1 two groups of patient outcomes of table compare [example（%）]
| Group | Number of cases | Recovery from illness | It is effective | Effectively | It is invalid | Total effective rate |
| Observation group | 23 | 10 | 6 | 5 | 2 | 91.30* |
| Control group | 23 | 4 | 5 | 6 | 8 | 65.22 |
Note：Compare with control group, * P<0.05.
2.2 safety evaluatio
Two groups of patients are without there is serious adverse reaction in therapeutic process.But there is 1 patient in observation group patient in the 1st clothes
Occur having a stomach upset after medicine, after take traditional Chinese herbal decoction and do not occur the situation of having a stomach upset again after being gargled with water.Control group patient
In there are 5 patients to occur gastral cavilty portion pain after taking medicine again, 3 patient pains do not occur pain again after alleviating.
Claims (8)
1. it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition, it is characterised in that be made the group of the bulk drug of the pharmaceutical composition
It is into weight portion：
10000 years moss 420-430 weight portion Gardenoside 230-260 weight portion sanguisorbins of trifid sopubia herb 5200-5300 weight portions
II50-60 weight portion Doryopteris concolor (Langsd et Fisch.) Kuhn 700-900 weight portions.
2. according to claim 1 it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition, it is characterised in that be made the medicine
The composition and weight portion of the bulk drug of composition be：
5250 weight portion of trifid sopubia herb, 10000 years weight portion sanguisorbin II55 weight portions of 425 weight portion Gardenoside of moss 245 are black
The weight portion of heart fern 800.
3. according to claim 1 it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition, it is characterised in that pharmaceutical composition
Piece agent or capsule or dripping pill can be prepared using the conventional method of galenic pharmacy.
4. according to claim 1 it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition, it is characterised in that pharmaceutical composition
The preventing and treating protrusion of lumber intervertebral disc medicine constituted with chemical drugs or Chinese medicine.
5. it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition preparation method, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：10000 years moss 420-430 weight portion Gardenosides of trifid sopubia herb 5200-5300 weight portions
230-260 weight portion sanguisorbin II50-60 weight portion Doryopteris concolor (Langsd et Fisch.) Kuhn 700-900 weight portions；
Preparation method：
（1）Trifid sopubia herb, 10000 years moss, Gardenoside, sanguisorbin II, Doryopteris concolor (Langsd et Fisch.) Kuhns are taken by bulk drug proportioning, is mixed, use weight percent
Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 23%, and extraction time is 21 times, and each extraction time is 67 hours, molten every time
Agent consumption is 55 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close
Degree 1.03, filtration, liquid is first washed with water by SIP1300 large pore resin absorption columns, then with the second of weight percent concentration 12%
Alcoholic solution elutes SIP1300 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 12%, reclaims ethanol, concentration
Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 42% as solvent, heating and refluxing extraction 34 times is carried every time
The time is taken for 0.1 hour, each solvent load is 34 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned
Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water, then use weight by D151 large pore resin absorption columns
The ethanol solution of percent concentration 53% elutes D151 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 53%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. according to claim 5 it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition preparation method, it is characterised in that
Prepare as follows：
The composition and weight portion of bulk drug be：5250 weight portion of trifid sopubia herb, 10000 years weight portions of 425 weight portion Gardenoside of moss 245
The weight portion of sanguisorbin II55 weight portions Doryopteris concolor (Langsd et Fisch.) Kuhn 800；
Preparation method：
（1）Trifid sopubia herb, 10000 years moss, Gardenoside, sanguisorbin II, Doryopteris concolor (Langsd et Fisch.) Kuhns are taken by bulk drug proportioning, is mixed, use weight percent
Used as solvent, 38 DEG C of temperature extractions take the ethanol of specific concentration 23%, and extraction time is 21 times, and each extraction time is 67 hours, molten every time
Agent consumption is 55 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into relatively close
Degree 1.03, filtration, liquid is first washed with water by SIP1300 large pore resin absorption columns, then with the second of weight percent concentration 12%
Alcoholic solution elutes SIP1300 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 12%, reclaims ethanol, concentration
Dry, obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 42% as solvent, heating and refluxing extraction 34 times is carried every time
The time is taken for 0.1 hour, each solvent load is 34 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned
Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water, then use weight by D151 large pore resin absorption columns
The ethanol solution of percent concentration 53% elutes D151 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 53%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. according to claim 5 it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition preparation method, it is characterised in that
Pharmaceutical composition can prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
8. according to claim 5 it is a kind of prevent and treat protrusion of lumber intervertebral disc pharmaceutical composition preparation method, it is characterised in that
Pharmaceutical composition and chemical drugs or Chinese medicine composition preventing and treating protrusion of lumber intervertebral disc medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611132975.5A CN106668285A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for preventing and curing lumbar disc herniation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611132975.5A CN106668285A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for preventing and curing lumbar disc herniation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106668285A true CN106668285A (en) | 2017-05-17 |
Family
ID=58867901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611132975.5A Withdrawn CN106668285A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for preventing and curing lumbar disc herniation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106668285A (en) |
-
2016
- 2016-12-10 CN CN201611132975.5A patent/CN106668285A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105343625A (en) | Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof | |
| CN103263531B (en) | Chinese medicine composition for treating prosopalgia and preparation method thereof | |
| CN102000164A (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN103055285A (en) | Traditional Chinese medicine for treating forepart hepetocirrhosis and preparation method thereof | |
| CN105748901A (en) | Formula and preparation method of health-care beverage | |
| CN104623314A (en) | Medicine composition for treating dry mouth and bitter taste and preparation method thereof | |
| CN106668285A (en) | Pharmaceutical composition for preventing and curing lumbar disc herniation | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN105106696A (en) | Traditional Chinese medicinal composition for treating chronic prostatitis | |
| CN104840773A (en) | Traditional Chinese medicine composition for treating vertebral artery type cervical spondylopathy and method for preparing same | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors | |
| CN103736008B (en) | Treatment breast carcinoma pharmaceutical composition being concurrently good for side Benign Nodule and preparation method thereof | |
| CN106619978A (en) | Pharmaceutical composition for treating lumbar disc herniation | |
| CN106668284A (en) | Medicinal composition for preventing and treating lumbar disc herniation | |
| CN105920409A (en) | Medicinal preparation for treating Alzheimer disease and application of medicinal preparation | |
| CN106075180A (en) | A kind of Chinese medicine treating intravertebral anesthesia postoperative urine retention and preparation method thereof | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN105832856A (en) | Chinese medicinal preparation for treating hepatic and gall diseases and preparation method thereof | |
| CN106729101B (en) | Traditional Chinese medicine composition for treating post-circulation ischemic stroke and preparation method thereof | |
| CN105497145A (en) | Medicine composition for preventing and curing lung cancer and preparation method thereof | |
| CN106728299A (en) | It is a kind of to treat pharmaceutical composition of protrusion of lumber intervertebral disc and preparation method thereof | |
| CN105311578A (en) | Traditional Chinese medicine composition for treating intracranial tumors | |
| CN104689073A (en) | Medicine for treating yin deficiency and heat-poison type lung cancer and preparation method thereof | |
| CN105250905A (en) | Traditional Chinese medicine composition for treating postpartum uterus subinvol ution and preparation method thereof | |
| CN104840864A (en) | Traditional Chinese medicine preparation for treating infantile diarrhea caused by spleen deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170517 |
|
| WW01 | Invention patent application withdrawn after publication |